|

Ivonescimab (20mg/kg Q3W) Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: AK112, PD-1 / VEGF bispecific antibody, SMT112, 依达方® (Yiwoxi Dankang Zhusheye)

Pipeline

Phase 2: 2

Top Sponsors

  • Zhejiang Cancer Hospital1
  • QuantumLeap Healthcare Collaborative1

Indications

  • Cancer2
  • AK1121
  • Hormone Receptor Negative Tumor1
  • Hormone Receptor Positive Tumor1
  • Angiosarcoma1

Other1 trial

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Phase 2

Birmingham, Alabama1 trial

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.